Herpes Cure Advocacy (HCA) has joined CPIC as a new patient advocacy group working to prevent neonatal herpes. HCA is a grassroots, membership-based international organization of more than 14,000 patient advocates with the goal of a cure, treatment, and prevention for HSV types 1 and 2. Recent advocacy from HCA has led to the first-ever national strategy and strategic plan from the Office of the Assistant Secretary for Health for the treatment and prevention of herpes in the FY 2022 budget.
HCA recently launched a Neonatal Herpes Advocacy Task Force to provide community for impacted families; engage with stakeholders, physicians, and scientists; and create change to better protect American families from neonatal herpes. The kickoff meeting will be held September 14, 2022, at 6 pm EDT. Families, clinicians, professionals, policy workers, and advocates for change are all welcome. To register and receive an email confirmation with instructions to join the meeting, click here. For more information, please visit the HCA website.
The Congenital and Perinatal Infections Consortium (CPIC) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). CPIC is funded under grant number U54AI150225 as a collaboration between NCATS and the National Institute of Allergy and Infectious Diseases (NIAID).